Rhythm Pharmaceuticals, a commercial-stage biopharmaceutical specialist in rare neuroendocrine obesity disorders, continues expanding its lead product IMCIVREE into new indications such as acquired hypothalamic obesity. Despite persistent operating losses and negative cash flow reflecting early commercialization and R&D investments, the company leverages regulatory milestones and pipeline assets bivamelagon and RM-718 to broaden patient reach. With IMCIVREE approved across major markets and ongoing pivotal trials, Rhythm stands at a critical juncture to demonstrate sustainable revenue growth against significant regulatory, commercialization, and capital risks.